1
|
Mouton W, Oriol G, Compagnon C, Saade C, Saker K, Franc P, Mokdad B, Fleurie A, Lacoux X, Daniel S, Berthier F, Barnel C, Pozzetto B, Fassier JB, Dubois V, Djebali S, Dubois M, Walzer T, Marvel J, Brengel-Pesce K, Trouillet-Assant S. Combining SARS-CoV-2 interferon-gamma release assay with humoral response assessment to define immune memory profiles. Eur J Immunol 2024; 54:e2451035. [PMID: 38627984 DOI: 10.1002/eji.202451035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 03/21/2024] [Accepted: 03/22/2024] [Indexed: 07/07/2024]
Abstract
OBJECTIVES In the post-SARS-CoV-2 pandemic era, "breakthrough infections" are still documented, due to variants of concerns (VoCs) emergence and waning humoral immunity. Despite widespread utilization, the definition of the anti-Spike (S) immunoglobulin-G (IgG) threshold to define protection has unveiled several limitations. Here, we explore the advantages of incorporating T-cell response assessment to enhance the definition of immune memory profile. METHODS SARS-CoV-2 interferon-gamma release assay test (IGRA) was performed on samples collected longitudinally from immunocompetent healthcare workers throughout their immunization by infection and/or vaccination, anti-receptor-binding domain IgG levels were assessed in parallel. The risk of symptomatic infection according to cellular/humoral immune capacities during Omicron BA.1 wave was then estimated. RESULTS Close to 40% of our samples were exclusively IGRA-positive, largely due to time elapsed since their last immunization. This suggests that individuals have sustained long-lasting cellular immunity, while they would have been classified as lacking protective immunity based solely on IgG threshold. Moreover, the Cox regression model highlighted that Omicron BA.1 circulation raises the risk of symptomatic infection while increased anti-receptor-binding domain IgG and IGRA levels tended to reduce it. CONCLUSION The discrepancy between humoral and cellular responses highlights the significance of assessing the overall adaptive immune response. This integrated approach allows the identification of vulnerable subjects and can be of interest to guide antiviral prophylaxis at an individual level.
Collapse
Affiliation(s)
- William Mouton
- CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Guy Oriol
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Christelle Compagnon
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Carla Saade
- CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Kahina Saker
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Priscille Franc
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Bouchra Mokdad
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Aurore Fleurie
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Xavier Lacoux
- R&D - Immunoassay, bioMerieux S.A., Marcy l'Etoile, France
| | - Soizic Daniel
- R&D - Immunoassay, bioMerieux S.A., Marcy l'Etoile, France
| | - Franck Berthier
- R&D - Life Sciences, bioMerieux S.A., Marcy l'Etoile, France
| | - Cécile Barnel
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Bruno Pozzetto
- CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France
- Department of Infectious Agents and Hygiene, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France
| | - Jean-Baptiste Fassier
- Department of Occupational Health and Medicine, Hospices Civils de Lyon, Lyon, France
- UMRESTTE (UMR T9405), Université Claude Bernard Lyon 1, Lyon, France
| | - Valérie Dubois
- Etablissement Français du Sang Auvergne Rhône Alpes, Laboratoire HLA de Lyon, Décines, France
| | - Sophia Djebali
- CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France
| | - Maxence Dubois
- CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France
| | - Thierry Walzer
- CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France
| | - Jacqueline Marvel
- CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France
| | - Karen Brengel-Pesce
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| | - Sophie Trouillet-Assant
- CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France
- Joint Research Unit Hospices Civils de Lyon-bioMerieux S.A., Hôpital Lyon Sud, Pierre-Bénite, France
| |
Collapse
|
2
|
Domènech-Montoliu S, Puig-Barberà J, Pac-Sa MR, Orrico-Sanchéz A, Gómez-Lanas L, Sala-Trull D, Domènech-Leon C, Del Rio-González A, Sánchez-Urbano M, Satorres-Martinez P, Aparisi-Esteve L, Badenes-Marques G, Blasco-Gari R, Casanova-Suarez J, Gil-Fortuño M, Hernández-Pérez N, Jovani-Sales D, López-Diago L, Notari-Rodríguez C, Pérez-Olaso O, Romeu-Garcia MA, Ruíz-Puig R, Arnedo-Pena A. Cellular Immunity of SARS-CoV-2 in the Borriana COVID-19 Cohort: A Nested Case-Control Study. EPIDEMIOLOGIA 2024; 5:167-186. [PMID: 38651389 PMCID: PMC11036210 DOI: 10.3390/epidemiologia5020012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2024] [Revised: 03/27/2024] [Accepted: 04/05/2024] [Indexed: 04/25/2024] Open
Abstract
Our goal was to determine the cellular immune response (CIR) in a sample of the Borriana COVID-19 cohort (Spain) to identify associated factors and their relationship with infection, reinfection and sequelae. We conducted a nested case-control study using a randomly selected sample of 225 individuals aged 18 and older, including 36 individuals naïve to the SARS-CoV-2 infection and 189 infected patients. We employed flow-cytometry-based immunoassays for intracellular cytokine staining, using Wuhan and BA.2 antigens, and chemiluminescence microparticle immunoassay to detect SARS-CoV-2 antibodies. Logistic regression models were applied. A total of 215 (95.6%) participants exhibited T-cell response (TCR) to at least one antigen. Positive responses of CD4+ and CD8+ T cells were 89.8% and 85.3%, respectively. No difference in CIR was found between naïve and infected patients. Patients who experienced sequelae exhibited a higher CIR than those without. A positive correlation was observed between TCR and anti-spike IgG levels. Factors positively associated with the TCR included blood group A, number of SARS-CoV-2 vaccine doses received, and anti-N IgM; factors inversely related were the time elapsed since the last vaccine dose or infection, and blood group B. These findings contribute valuable insights into the nuanced immune landscape shaped by SARS-CoV-2 infection and vaccination.
Collapse
Affiliation(s)
| | - Joan Puig-Barberà
- Vaccines Research Unit, Foundation for the Promotion of Health and Biomedical Research in Valencia Region FISABIO-Public Health, 46020 Valencia, Spain; (J.P.-B.); (A.O.-S.)
| | - María Rosario Pac-Sa
- Public Health Center, 12003 Castelló de la Plana, Spain; (M.R.P.-S.); (M.A.R.-G.)
| | - Alejandro Orrico-Sanchéz
- Vaccines Research Unit, Foundation for the Promotion of Health and Biomedical Research in Valencia Region FISABIO-Public Health, 46020 Valencia, Spain; (J.P.-B.); (A.O.-S.)
- Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Secretary of Chair of Vaccines Catholic University of Valencia, 46001 Valencia, Spain
| | - Lorna Gómez-Lanas
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain; (L.G.-L.); (D.S.-T.); (M.S.-U.); (P.S.-M.); (G.B.-M.); (R.B.-G.); (D.J.-S.); (C.N.-R.); (R.R.-P.)
| | - Diego Sala-Trull
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain; (L.G.-L.); (D.S.-T.); (M.S.-U.); (P.S.-M.); (G.B.-M.); (R.B.-G.); (D.J.-S.); (C.N.-R.); (R.R.-P.)
| | - Carmen Domènech-Leon
- Department of Medicine, University CEU Cardenal Herrera, 12006 Castelló de la Plana, Spain;
| | | | - Manuel Sánchez-Urbano
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain; (L.G.-L.); (D.S.-T.); (M.S.-U.); (P.S.-M.); (G.B.-M.); (R.B.-G.); (D.J.-S.); (C.N.-R.); (R.R.-P.)
| | - Paloma Satorres-Martinez
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain; (L.G.-L.); (D.S.-T.); (M.S.-U.); (P.S.-M.); (G.B.-M.); (R.B.-G.); (D.J.-S.); (C.N.-R.); (R.R.-P.)
| | | | - Gema Badenes-Marques
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain; (L.G.-L.); (D.S.-T.); (M.S.-U.); (P.S.-M.); (G.B.-M.); (R.B.-G.); (D.J.-S.); (C.N.-R.); (R.R.-P.)
| | - Roser Blasco-Gari
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain; (L.G.-L.); (D.S.-T.); (M.S.-U.); (P.S.-M.); (G.B.-M.); (R.B.-G.); (D.J.-S.); (C.N.-R.); (R.R.-P.)
| | | | - María Gil-Fortuño
- Microbiology Service University Hospital de la Plana, 12540 Vila-real, Spain; (M.G.-F.); (N.H.-P.); (O.P.-O.)
| | - Noelia Hernández-Pérez
- Microbiology Service University Hospital de la Plana, 12540 Vila-real, Spain; (M.G.-F.); (N.H.-P.); (O.P.-O.)
| | - David Jovani-Sales
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain; (L.G.-L.); (D.S.-T.); (M.S.-U.); (P.S.-M.); (G.B.-M.); (R.B.-G.); (D.J.-S.); (C.N.-R.); (R.R.-P.)
| | - Laura López-Diago
- Clinical Analysis Service University Hospital de la Plana, 12540 Vila-real, Spain;
| | - Cristina Notari-Rodríguez
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain; (L.G.-L.); (D.S.-T.); (M.S.-U.); (P.S.-M.); (G.B.-M.); (R.B.-G.); (D.J.-S.); (C.N.-R.); (R.R.-P.)
| | - Oscar Pérez-Olaso
- Microbiology Service University Hospital de la Plana, 12540 Vila-real, Spain; (M.G.-F.); (N.H.-P.); (O.P.-O.)
| | | | - Raquel Ruíz-Puig
- Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain; (L.G.-L.); (D.S.-T.); (M.S.-U.); (P.S.-M.); (G.B.-M.); (R.B.-G.); (D.J.-S.); (C.N.-R.); (R.R.-P.)
| | - Alberto Arnedo-Pena
- Public Health Center, 12003 Castelló de la Plana, Spain; (M.R.P.-S.); (M.A.R.-G.)
- Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Department of Health Science, Public University Navarra, 31006 Pamplona, Spain
| |
Collapse
|
3
|
Mihaescu G, Chifiriuc MC, Filip R, Bleotu C, Ditu LM, Constantin M, Cristian RE, Grigore R, Bertesteanu SV, Bertesteanu G, Vrancianu CO. Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection. Front Immunol 2024; 14:1273604. [PMID: 38288121 PMCID: PMC10822962 DOI: 10.3389/fimmu.2023.1273604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Accepted: 12/29/2023] [Indexed: 01/31/2024] Open
Abstract
Mammalians sense antigenic messages from infectious agents that penetrate the respiratory and digestive epithelium, as well as signals from damaged host cells through membrane and cytosolic receptors. The transduction of these signals triggers a personalized response, depending on the nature of the stimulus and the host's genetics, physiological condition, and comorbidities. Interferons (IFNs) are the primary effectors of the innate immune response, and their synthesis is activated in most cells within a few hours after pathogen invasion. IFNs are primarily synthesized in infected cells, but their anti-infective effect is extended to the neighboring cells by autocrine and paracrine action. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in 2019 was a stark reminder of the potential threat posed by newly emerging viruses. This pandemic has also triggered an overwhelming influx of research studies aiming to unveil the mechanisms of protective versus pathogenic host immune responses induced by SARS-CoV-2. The purpose of this review is to describe the role of IFNs as vital players in the battle against SARS-CoV-2 infection. We will briefly characterize and classify IFNs, present the inductors of IFN synthesis, their sensors, and signaling pathways, and then discuss the role of IFNs in controlling the evolution of SARS-CoV-2 infection and its clinical outcome. Finally, we will present the perspectives and controversies regarding the prophylactic and therapeutic potential of IFNs in SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Grigore Mihaescu
- Microbiology Immunology Department, Faculty of Biology, University of Bucharest, Bucharest, Romania
- The Research Institute of the University of Bucharest, Bucharest, Romania
| | - Mariana Carmen Chifiriuc
- Microbiology Immunology Department, Faculty of Biology, University of Bucharest, Bucharest, Romania
- The Research Institute of the University of Bucharest, Bucharest, Romania
- Department of Life, Medical and Agricultural Sciences, Biological Sciences Section, Academy of Romanian Scientists, Bucharest, Romania
| | - Roxana Filip
- Faculty of Medicine and Biological Sciences, Stefan cel Mare University of Suceava, Suceava, Romania
- Microbiology Department, Suceava Emergency County Hospital, Suceava, Romania
| | - Coralia Bleotu
- The Research Institute of the University of Bucharest, Bucharest, Romania
- Cellular and Molecular Pathology Department, Stefan S. Nicolau Institute of Virology, Bucharest, Romania
| | - Lia Mara Ditu
- Microbiology Immunology Department, Faculty of Biology, University of Bucharest, Bucharest, Romania
| | - Marian Constantin
- The Research Institute of the University of Bucharest, Bucharest, Romania
- Institute of Biology of Romanian Academy, Bucharest, Romania
| | - Roxana-Elena Cristian
- The Research Institute of the University of Bucharest, Bucharest, Romania
- Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, Bucharest, Romania
| | - Raluca Grigore
- ENT Department, University of Medicine and Pharmacy Carol Davila and Coltea Clinical Hospital, Bucharest, Romania
| | - Serban Vifor Bertesteanu
- ENT Department, University of Medicine and Pharmacy Carol Davila and Coltea Clinical Hospital, Bucharest, Romania
| | - Gloria Bertesteanu
- ENT Department, University of Medicine and Pharmacy Carol Davila and Coltea Clinical Hospital, Bucharest, Romania
| | - Corneliu Ovidiu Vrancianu
- Microbiology Immunology Department, Faculty of Biology, University of Bucharest, Bucharest, Romania
- The Research Institute of the University of Bucharest, Bucharest, Romania
- DANUBIUS Department, National Institute of Research and Development for Biological Sciences, Bucharest, Romania
| |
Collapse
|
4
|
Tani Y, Takita M, Wakui M, Saito H, Nishiuchi T, Zhao T, Yamamoto C, Kawamura T, Sugiyama A, Nakayama A, Kaneko Y, Kodama T, Shinaha R, Tsubokura M. Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: a cohort study from the Fukushima vaccination community survey, Japan. Front Immunol 2023; 14:1240425. [PMID: 37662950 PMCID: PMC10469480 DOI: 10.3389/fimmu.2023.1240425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Accepted: 07/28/2023] [Indexed: 09/05/2023] Open
Abstract
The bivalent mRNA vaccine is recommended to address coronavirus disease variants, with additional doses suggested for high-risk groups. However, the effectiveness, optimal frequency, and number of doses remain uncertain. In this study, we examined the long-term cellular and humoral immune responses following the fifth administration of the mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients undergoing hemodialysis. To our knowledge, this is the first study to monitor long-term data on humoral and cellular immunity dynamics in high-risk populations after five doses of mRNA vaccination, including the bivalent mRNA vaccine. Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity. The absence of a relationship between positive controls and T-Spot reactivity suggests that these immune alterations were specific to SARS-CoV-2. In multivariable analysis, participants aged ≥70 years showed a marginally significant lower likelihood of having reactive results. Notably, among the 14 individuals who received heterologous vaccines, 13 successfully acquired cellular immunity, supporting the effectiveness of this administration strategy. These findings provide valuable insights for future vaccination strategies in vulnerable populations. However, further research is needed to evaluate the involvement of immune tolerance and exhaustion through repeated vaccination to optimize immunization strategies.
Collapse
Affiliation(s)
- Yuta Tani
- Medical Governance Research Institute, Tokyo, Japan
| | - Morihito Takita
- Medical Governance Research Institute, Tokyo, Japan
- Department of Radiation Health Management, Fukushima Medical University, Fukushima, Japan
| | - Masatoshi Wakui
- Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Hiroaki Saito
- Department of Radiation Health Management, Fukushima Medical University, Fukushima, Japan
- Department of Internal Medicine, Soma Central Hospital, Fukushima, Japan
| | | | - Tianchen Zhao
- Department of Radiation Health Management, Fukushima Medical University, Fukushima, Japan
| | - Chika Yamamoto
- Department of Radiation Health Management, Fukushima Medical University, Fukushima, Japan
| | - Takeshi Kawamura
- Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan
- Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
| | - Akira Sugiyama
- Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan
| | - Aya Nakayama
- Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan
| | - Yudai Kaneko
- Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
- Medical and Biological Laboratories Co., Ltd, Tokyo, Japan
| | - Tatsuhiko Kodama
- Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
| | - Ryuzaburo Shinaha
- Department of Internal Medicine, Soma Central Hospital, Fukushima, Japan
| | - Masaharu Tsubokura
- Medical Governance Research Institute, Tokyo, Japan
- Department of Radiation Health Management, Fukushima Medical University, Fukushima, Japan
- Department of Internal Medicine, Soma Central Hospital, Fukushima, Japan
| |
Collapse
|